Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      

This page is updated frequently with new Mammal-related patent applications.




Date/App# patent app List of recent Mammal-related patents
06/16/16
20160170060 
 Monitoring system, components, methods, and applications patent thumbnailMonitoring system, components, methods, and applications
A real-time, marine acoustic monitoring system and method for detecting, tracking, recording, analyzing, communicating and otherwise obtaining and manipulating data indicative of marine presence and/or activity, and using such data to avoid or mitigate detrimental impact on the marine environment. The system includes sub-sea instrumentation packages (sps) including sensors recording acoustic signals and other sensor data that allow elapsed and/or real-time, in-situ data communications and control of the individual instrumentation packages and system configuration.
Fairfield Industries Incorporated D/b/a Fairfieldnodal


06/16/16
20160168588 
 Methods of producing long acting ctp-modified polypeptides patent thumbnailMethods of producing long acting ctp-modified polypeptides
Disclosed herein is a method for manufacturing a recombinant polypeptide of interest modified by a ctp extension in a mammalian cells culture system.. .
Opko Biologics Ltd


06/16/16
20160168572 
 Delivery of therapeutic agent patent thumbnailDelivery of therapeutic agent
A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a dna sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g.
Vl27,inc.


06/16/16
20160168533 
 Isolation, expansion and use of clonogenic endothelial progenitor cells patent thumbnailIsolation, expansion and use of clonogenic endothelial progenitor cells
A hierarchy of endothelial colony forming cells (epcs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential-endothelial colony forming cell (hpp-ecfc) was isolated and characterized.
Indiana University Research And Technology Corporation


06/16/16
20160168227 
 Composition and vaccine for treating lung cancer patent thumbnailComposition and vaccine for treating lung cancer
The present invention relates to a composition comprising at least one mrna encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5t4 (trophoblast glycoprotein, tpbg), survivin (baculoviral tap repeat-containing protein 5; birc5), ny-eso-1 (new york esophageal squamous cell carcinoma 1, ctag1b), mage-c1 (melanoma antigen family c1), mage-c2 (melanoma antigen family c2), and muc1 (mucin 1). The invention furthermore relates to a vaccine comprising at least one mrna encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (nsclc), and diseases or disorders related thereto.
Curevac Ag


06/16/16
20160168105 
 Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide patent thumbnailFormulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a jnk pathway in mammals using such pharmaceutical compositions or dosage forms.
Signal Pharmaceuticals, Llc


06/16/16
20160166845 
 Dynamic multi-layer therapeutic magnetic device patent thumbnailDynamic multi-layer therapeutic magnetic device
A multi-layer magnetic device comprising two or more layers of containing magnets or ferromagnetic material to be applied to areas of the body of a mammal in which the first layer has one or more protrusions and the second layer has one or more receiving zones that are positioned to align with the protrusions of the first layer. At least a portion of the first layer has a first magnetic pattern, and at least a portion of the second layer has a second magnetic pattern such that, when the protrusions are aligned with the receiving zones, at least one region of the first magnetic pattern faces at least one region of the second magnetic pattern of like polarity thereby repulsing one another..
Nikken International, Inc.


06/16/16
20160166754 
 Unitary body systems and devices and methods to use the same for retroperfusion patent thumbnailUnitary body systems and devices and methods to use the same for retroperfusion
Unitary body systems and devices and methods to use the same for retroperfusion. In an exemplary device embodiment of the present disclosure, the device comprises a unitary body having a wall and a lumen defined therethrough, a first portion terminating at a first end and configured for at least partial placement within a mammalian artery, a first one-way valve positioned at or near an end of the first portion opposite the first end, a second portion terminating at a second end and configured for at least partial placement within a mammalian vein, and a second one-way valve positioned at or near an end of the second portion opposite the second end..
Cvdevices, Llc


06/16/16
20160166735 
 Injectable composition for in-situ repair and regeneration of an injured ligament or tendon and methods of use patent thumbnailInjectable composition for in-situ repair and regeneration of an injured ligament or tendon and methods of use
The invention provides an injectable composition and method for the minimally invasive, in-situ repair and regeneration of an injured ligament or tendon in a mammalian subject. The composition is also useful for the delivery of growth factors, therapeutic agents and cells into the area of tendon or ligament injury..
The Board Of Trustees Of The Leland Stanford Junior University


06/16/16
20160166730 
 Biocompatable annular prostheses and methods for forming same patent thumbnailBiocompatable annular prostheses and methods for forming same
Annular prostheses comprising an elongated tubular member formed from an extracellular matrix (ecm) composition comprising ecm from a mammalian tissue source, which, when disposed proximate damaged cardiovascular tissue, induces modulated healing, including modulation of inflammation and bioremodeling. The ecm can also be augmented with a supplemental biologically active agent, such as a growth factor, to enhance modulation of inflammation and bioremodeling..
Cormatrix Cardiovascular, Inc.


06/16/16
20160166718 

Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease


Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human.
Unity Biotechnology, Inc.


06/16/16
20160166710 

Method for increasing expression of rna-encoded proteins


The invention relates to an rna comprising at least one open reading frame (orf) and comprising at least one modification, which increases the expression of the encoded peptide or protein. Furthermore, the invention relates to the medical use of such a modified rna administered to a subject by jet injection.
Curevac Ag


06/16/16
20160166709 

Methods and compositions for treating brain diseases


The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an raav particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of aav inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (csf) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the csf for distribution to the brain.. .
University Of Iowa Research Foundation


06/16/16
20160166668 

Composition and vaccine for treating prostate cancer


The present invention relates to a composition comprising at least one mrna encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of psa (prostate-specific antigen), psma (prostate-specific membrane antigen), psca (prostate stem cell antigen), steap (six transmembrane epithelial antigen of the prostate), muc1 (mucin 1) and pap (prostatic acid phosphatase). The invention furthermore relates to a vaccine comprising at least one mrna encoding such a combination of antigens and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (pca), preferably of prostate adenocarcinoma, locally limited, locally advanced, metastatic, castration-resistant (hormone-refractory), metastatic castration-resistant and non-metastatic castration-resistant prostate cancers, and diseases or disorders related thereto.
Curevac Ag


06/16/16
20160166662 

Use of attenuated strains of parasites for the prevention or treatment of pathologies associates with an apicomplexan


Strains of sarcocystidae selected from toxoplasma spp or neospora spp isolated from their natural environment and having an immunostimulant effect, for the use thereof in the prevention or the treatment, in a mammal, of a pathology associated with an apicomplexan of the family cryptosporidiidae.. .
Universite Francois Rabelais De Tours


06/16/16
20160166652 

Novel n- and c-terminal substituted antagonistic analogs of gh-rh


There is provided a novel series of synthetic analogs of hgh-rh(1-29)nh2 (seq id no: 1) and hgh-rh(1-30)nh2. Of particular interest are those carrying phac, n-me-aib, dca, ac-ada, fer, ac-amc, me-nh-sub, phac-ada, ac-ada-d-phe, ac-ada-phe, dca-ada, dca-amc, nac-ada, ada-ada, or ch3—(ch2)10—co-ada, at the n-terminus and β-ala, amc, apa, ada, ae2a, ae4p, ε-lys(α-nh2), agm, lys(oct) or ahx, at the c-terminus.
U.s.a., Represented By The Department Of Veterans Affairs


06/16/16
20160166633 

Methods and compositions for the prevention and treatment of friedreich's ataxia


The disclosure provides methods of preventing or treating friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with friedreich's ataxia, and/or reducing the likelihood or severity of friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof..
Stealth Bio Therapeutics Corp


06/16/16
20160166626 

Topical compositions and methods for reducing oxidative stress


A composition for the topical application on a mammalian skin comprises one or more brassica plant extracts selected from the group consisting of: brassica juncea extract, brassica oleracea italica extract, brassica oleracea capitata extract, brassica oleracea botrytis extract, and brassica oleracea acephala extract. The composition further comprises one or more selected from the group consisting of: curcuma longa extract, curcuminoids, tetrahydrocurcuminoids, metabolites of curcuminoids or tetrahydrocurcuminoids, and derivatives of curcuminoids or tetrahydrocurcuminoids.
Lifevantage Corporation


06/16/16
20160166620 

Encapsulated cells for hormone replacement therapy


A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition.
Wake Forest University Health Sciences


06/16/16
20160166618 

Treatment of pain using amnion derived adherent cells


Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent amnion-derived cells (amdacs). Because mammalian placentas are plentiful and are normally discarded as medical waste, they represent a unique source of medically-useful stem cells..
Anthrogenesis Corproation


06/16/16
20160166557 

Antiviral agents


A pharmaceutically acceptable salt thereof or solvate thereof or mixtures thereof. The subject can be an animal, particularly mammals and more particularly humans and companion animals such as cats and dogs..

06/16/16
20160166417 

Gastric restriction devices for treating obesity


A gastric restraining device for treating excessive weight or obesity in mammals. The gastric restraining device includes an elastomeric sheet configured to be placed around a stomach of a mammal, an ablation device attached to the elastomeric sheet, the ablation device configured to emit energy toward an outer surface of the stomach when the elastomeric sheet is placed around the stomach, and an energy device coupled to the ablation device to generate the energy and to transfer the energy to the ablation device..

06/16/16
20160166387 

Implantable lubrication device and treating a human or mammal patient by means of the device


A lubrication device for lubricating a joint of a human or mammal patient, which is entirely implantable in a patient's body, comprises a reservoir for storing a lubricating fluid and a fluid connection for introducing the lubricating fluid into the joint when the device is implanted in the patient's body. Further, the fluid connection comprises a fluid connection device connecting the reservoir with the joint such that a lubricating fluid flow is established from the reservoir into the joint.

06/16/16
20160165922 

Method to increase milk production by mammals


This invention relates to the administration of an animal immunoglobulin source to mammals such as dairy cattle to improve milk production without negatively affecting reproductive parameters.. .
The Lauridsen Group, Inc.


06/16/16
20160165886 

Compositions and methods for repelling blood-sucking and biting insects, ticks and mites


Chromene derivatives based on a chromene amide isolated from amyris texana. Also disclosed are compositions containing chromene derivatives (synthetic or natural) based on a chromene amide isolated from amyris texana.
The United States Of America, As Represented By The Secretary Of Agriculture


06/16/16
20160165862 

Animal models and therapeutic molecules


The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited; The Bennet Building (b930)


06/09/16
20160160228 

Transgenic aloe plants for production of proteins and related methods


The present inventions provide transgenic aloe plants and recombinant constructs for transforming aloe plants, aspects of which, may be applied to other monocots. The recombinant constructs may include one or more dna sequences encoding mammalian proteins and at least one promoter capable of directing the expression of recombinant proteins in an aloe plant.
Thegreencell, Inc.


06/09/16
20160160180 

Osteoblast and preparing same


The present invention relates to: a method of preparing an osteoblast from a somatic cell of a mammal, the method including introducing a bone-related gene or an expression product thereof and a reprogramming-related gene or an expression product thereof, or introducing a reprogramming-related gene or an expression product thereof independently into the somatic cell, the bone-related gene including at least one kind selected from the group consisting of runx2 (r), osterix (o), and dlx5 (d), the reprogramming-related gene including at least one kind selected from the group consisting of oct family, c-myc (m), l-myc (l), klf family, lin-28, and sox2; and an osteoblast prepared by the method.. .
Kyoto Prefectural Public University Corporation


06/09/16
20160159851 

Inhibitors of the farnesoid x receptor and uses in medicine


Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least cone compound of the invention, a method of method of inhibiting a farnesoid x receptor in a mammal, and a method of treating or preventing obesity in a mammal..
The Penn State Research Foundation


06/09/16
20160159797 

Pyrazolo[3,4-c]pyridine compounds and methods of use


Pyrazolo[3,4-c]pyridine compounds of formula i, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein r1 and r2 are as defined herein, are useful for inhibiting pim kinase, and for treating disorders such as cancer mediated by pim kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
Genentech, Inc.


06/09/16
20160158406 

Self-assembling biomimetic hydrogels having bioadhesive properties


The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal.
Rowan University


06/09/16
20160158314 

Glycosylated protein of an extra-cellular matrix for use in a treating an ischemic heart of a human or animal subject in need thereof


The present invention relates to a glycosylated protein of an extracellular matrix, preferably of a mammalian extra-cellular matrix for use in a method of treating an ischemic heart of a human or animal subject in need thereof, a pharmaceutical composition comprising said glycosylated protein and a method for the in vitro production of differentiated cardiomyocytes.. .
Fraunhofer-gesellschaft Zur FÖrderung Der Angewandten Forschung E.v.


06/09/16
20160158295 

Compositions and methods


Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition..
Seres Therapeutics, Inc.


06/09/16
20160158294 

Methods of populating a gastrointestinal tract


Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore forming bacteria.
Seres Therapeutics, Inc.


06/09/16
20160158249 

Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues


Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an glucocorticoid derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described..
Allergan, Inc.


06/09/16
20160158248 

Methods and systems for the delivery of a therapeutic agent


The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration.
University Of Iceland


06/09/16
20160158209 

Compounds for treatment of alzheimer's disease


The invention is directed to the use of a compound of formula i, as defined herein, to a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing a compound of formula i, and to a combination of a compound of formula i with a pharmacologically effective cholinesterase inhibitor to treat a mammal, including a human, for a disorder or condition selected from the list including alzheimer's disease, huntington's disease, parkinson's disease, non-alzheimer's dementias and als.. .
Medisynergics, Llc


06/09/16
20160157468 

Transgenic non-human mammal for producing chimeric human immunoglobulin e antibodies


The invention relates to a transgenic non-human mammal comprising human immunoglobulin mu and epsilon heavy-chain constant transgenes cμ and cε inserted in place of endogenous mu heavy-chain switch sequence sμ, and its use for producing chimeric human immunoglobulin e antibodies specific for an antigen of interest.. .
Université De Limoges


06/02/16
20160153999 

Selective capture and release of rare mammalian cells using photodegradable hydrogels in a microfluidic platform


Disclosed herein are photodegradable hydrogels and associated kits for selectively capturing and releasing cells. The hydrogels result from cross linking in the presence of a photoinitiator (1) a macromer having a polymeric backbone structure, a photo labile moiety, and a first linking moiety, and (2) a cell-binding moiety having a second linking moiety.
The General Hospital Corporation


06/02/16
20160153988 

Compositions and methods for the detection of anaplasma platys


Described herein are improved diagnostic tools for veterinary and human use which can be used for serodiagnosing a. Platys in mammals, particularly in members of the canidae family and in humans.
Ohio State Innovation Foundation


06/02/16
20160153878 

Device and methods


The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. Blood.
Epona Biotech Ltd


06/02/16
20160153020 

Methods for producing sialylated therapeutic proteins


The present invention relates to a transformed mammalian cell including a heterologous nucleic acid sequence (i) encoding a polypeptide including the catalytic domain of st6gal1 or of st6gal2 and, optionally, at least one nucleic acid sequence (ii) encoding a therapeutic protein including at least one glycosylation site, the transformed mammalian cell expressing the therapeutic protein with a sialylation on the at least one glycosylation site.. .
Glycotrek


06/02/16
20160152994 

Methods controlling gene expression


The present invention is in the field of genetics, especially plant genetics, and provides agents capable of controlling gene expression. The present invention specifically provides sequences of naturally occurring, tissue-specifically expressed micrornas.
Basf Plant Science Gmbh


06/02/16
20160152975 

Method for recombinant protein production in mammalian cells


Some embodiments relate to methods for the recombinant expression of a protein of interest in a mammalian host cell, use of an sh rna or an si rna directed against the galectin-1 gene for increasing the expression of a protein of interest in a mammalian host cell and kits comprising an shrna or an si rna and a cho cell.. .
UniversitÄt Bielefeld


06/02/16
20160152953 

Endogenous expression of hla-g and/or hla-e by mesenchymal cells


Methods and compositions are provided for the identification and isolation of mammalian hla-g+ msc, hla-e+ msc, or hla-g+/hla-e+ msc. The methods of the invention provide a means to obtain enriched hla-g+ msc, hla-e+ msc, or hla-g+/hla-e+ msc populations..
Escape Therapeutics, Inc.


06/02/16
20160152685 

Small molecule-dependent inteins and uses thereof


Elucidating the function of proteins in mammalian cells is particularly challenging due to the inherent complexity of these systems. Methods to study protein function in living cells ideally perturb the activity of only the protein of interest but otherwise maintain the natural state of the host cell or organism.
President And Fellows Of Harvard College


06/02/16
20160152681 

Anti-human papillomavirus 16 e6 t cell receptors


Disclosed is a t cell receptor (tcr) having antigenic specificity for an hla-a2-restricted epitope of human papillomavirus (hpv) 16 e6, e629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


06/02/16
20160152582 

Therapeutic compounds


Or salts thereof are provided. Pharmaceutical compositions comprising a compound of formula i′, processes for preparing compounds of formula i′, intermediates useful for preparing compounds of formula i′ and therapeutic methods for treating the proliferation of the hiv virus, treating aids or delaying the onset of aids or arc symptoms in a mammal are also provided..

06/02/16
20160151639 

Devices and methods for delivery of therapeutic energy


A device for insertion into a mammalian patient comprises a shaft and a light delivery element. The shaft comprises a proximal end, a distal end, and a lumen therebetween.
Oxys Ag


06/02/16
20160151459 

Therapeutic treating metabolic disorders


A method of treating metabolic disorders in a mammal is provided. The method comprises the step of administering to the mammal a meteorin-like protein or nucleic acid encoding a meteorin-like protein to the mammal..
Exerkine Corporation


06/02/16
20160151452 

Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof


The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals.
The Board Of Trustees Of The University Of Illinois


06/02/16
20160151445 

Methods for the regulation of matrix metalloproteinase expression


The disclosure provides methods of reducing mmp-9 expression and/or mmp-9 activity in a mammalian subject. The disclosure also provides methods of increasing timp-1 expression and/or timp-1 activity in a mammalian subject.
Stealth Bio Therapeutics Corp.


06/02/16
20160151444 

Methods for the prevention or treatment of vessel occlusion injury


The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof..
Stealth Peptides International, Inc.


06/02/16
20160151433 

Probiotic recolonisation therapy


The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of bacteroides, eubacteria, fusobacteria, propionibacteria, lactobacilli, anaerobic cocci, ruminococcus, e.

06/02/16
20160151432 

Probiotic recolonisation therapy


The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of bacteroides, eubacteria, fusobacteria, propionibacteria, lactobacilli, anaerobic cocci, ruminococcus, e.

06/02/16
20160151431 

Probiotic recolonisation therapy


The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of bacteroides, eubacteria, fusobacteria, propionibacteria, lactobacilli, anaerobic cocci, ruminococcus, e.

06/02/16
20160151429 

Probiotic recolonisation therapy


The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of bacteroides, eubacteria, fusobacteria, propionibacteria, lactobacilli, anaerobic cocci, ruminococcus, e.

06/02/16
20160151424 

Amniotic membrane preparations and purified compositions and anti-inflammation methods


Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating tgf β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues.
Tissuetech, Inc.


06/02/16
20160151415 

Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof


A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%.

06/02/16
20160151405 

Pappalysin regulator


A method is provided of decreasing or increasing the activity of a pappalysin polypeptide by decreasing or increasing the level of interacting pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide.
Aarhus Universitet


06/02/16
20160151380 

Therapies for diseases caused by arthropod-borne parasites


The present disclosure provides methods for treating or preventing diseases caused by arthropod-borne parasites by administration of a protein kinase inhibitor to a mammalian subject infected with or at risk of exposure to an arthropod-borne parasite. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in arthropods feeding on recipients of the regimens.
The Regents Of The University Of California


06/02/16
20160151379 

Combination therapies for malaria


The present disclosure provides methods for treating or preventing malaria by administration of a protein kinase inhibitor and optionally one or both of a further protein kinase inhibitor and an antimalarial drug to a mammalian subject infected with or at risk of exposure to plasmodium sp. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in mosquitoes feeding on recipients of the regimens.
The Regents Of The University Of California


06/02/16
20160151374 

Method of using vasoconstrictive agents during energy-based tissue therapy


A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation.
Covidien Ag


06/02/16
20160151343 

Non-flushing niacin analogues, and methods of use thereof


One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College


06/02/16
20160151308 

Cycloalkyl-diamines for neurodegenerative disorders


The invention is directed to the use of a compound of formula i as defined herein, a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing a compound of formula i, in treating a mammal, including a human, for a psychiatric disorder or condition selected from the group consisting of stroke, huntington's disease and amyotrophic lateral sclerosis (als).. .
Medisynergics, Llc


06/02/16
20160151305 

Agent or treatement and/or prevention of accelerated energy expenditure and/or diminished energy expenditure functionality


Disclosed herein is a solution that makes use of a food product that is effective for the detrimental decline of energy metabolism in humans and other mammals in need of treatment and/or prevention of accelerated energy expenditure and/or diminished energy expenditure functionality. The method disclosed herein continuously administers a functional food product rare sugar containing at least d-psicose to effectively improve energy expenditure..
Matsutani Chemical Industry Co., Ltd.


06/02/16
20160150768 

Animal models and therapeutic molecules


The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited


05/26/16
20160146816 

Tumor energy metabolism profiling


A diagnostic method for the prediction of tumor prognosis including the likelihood of formation of metastases or of relapse or local recurrence in tumor related diseases in a mammal and the provision of a therapy recommendation for a patient the enzyme activity of key enzymes of the energy metabolism is determined in fresh tumor tissue or fresh tumor cell mass after 24 hours incubation in a cell culture medium. Incubation reduces nutrition, drug and biopsy/surgery effects on the energy metabolism of the tissue slices or the cell mass.
UniversitÄt Heidelberg


05/26/16
20160146793 

Kits, compositions and methods for detecting a biological condition


The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject.. .
Leukodx Ltd.


05/26/16
20160145643 

Endothelial-targeted adenoviral vectors, methods and uses therefor


Disclosed are adenovirus vectors comprising a robo4 enhancer/promoter operatively linked to a transgene. Also disclosed are adenovirus vectors comprising a chimeric ad5-t4 phage fibritin shaft, a trimerization domain displaying a myeloid cell-binding peptide (mbp), and a robo4 enhancer promoter operatively linked to a transgene.
Washington University


05/26/16
20160145576 

Methods of producing stem cell conditioned media


Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury..
Neurofx, Inc.


05/26/16
20160145575 

Methods of generating cells with multilineage potential


The present invention relates to methods for generating mammalian multilineage-potential cells, including mesenchymal stem cells, comprising contacting mammalian somatic cells exhibiting a mature phenotype with pdgf-ab or functional derivative, fragment or mimetic thereof and azacitidine or functional derivative or analogue thereof for a time and under conditions sufficient to induce the transition of the somatic cells to cells exhibiting multilineage differentiative potential. Also provided are uses of said multilineage-potential cells, such as in promoting tissue repair and regeneration..
Newsouth Innovations Pty Limited


05/26/16
20160145327 

Compositions, devices, kits and methods for detecting hookworm


Methods, devices, kits and compositions for detecting the presence or absence of hookworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of hookworm in a fecal sample from a mammal that may also be infected with one or more of roundworm, whipworm, and heartworm.
Idexx Laboratories, Inc.


05/26/16
20160145291 

Therapeutic monosaccharide-based inhibitors of hexokinase and glucokinase for parasitic diseases, along with methods of their formation and use


Methods for treating a mammal that is infected by a parasitic organism are provided, along with pharmaceutical compositions and compounds. The method includes administering to the mammal the pharmaceutical composition of fig.
University Of South Carolina


05/26/16
20160144137 

Retractable insulin infusion system


A device for introducing a liquid (e.g., insulin) into tissue of a subject (e.g., a mammal, such as a human) in need of the liquid. The device includes a cannula having a distal tip.

05/26/16
20160144074 

Biological constructs for treating damaged organs and tissue


Biological constructs that can be engineered into a variety of shapes and employed to treat, augment and/or support damaged or diseased mammalian organs and/or tissue related thereto. The shapes include jackets and bands that are configured to encase a preselected region of a mammalian organ..
Cormatrix Cardiovascular, Inc.


05/26/16
20160144073 

Biological constructs for treating damaged organs and tissue


Biological constructs that can be engineered into a variety of shapes and employed to treat, augment and/or support damaged or diseased mammalian organs and/or tissue related thereto. The shapes include jackets and bands that are configured to encase a preselected region of a mammalian organ..
Cormatrix Cardiovascular, Inc.


05/26/16
20160144024 

Methods and compositions for preserving the viability of photoreceptor cells


Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering an apoptosis inhibitor to a mammal having an eye with retinal detachment.
Massachusetts Eye And Ear Infirmary


05/26/16
20160144015 

Bordetella outer-membrane protein antigens and methods of making and using the same


An isolated protein or peptide selected from the group consisting of bordetella colonization factor a (bcfa) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.. .
Wake Forest University Health Sciences


05/26/16
20160144014 

Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease


Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases.
Riken


05/26/16
20160144002 

Sickled erythrocytes and progenitors target cytotoxics to tumors


The present invention provides therapeutic mammalian cells which synthesize and express ss hemoglobin and a tumoricidal transgene. They are produced by transduction of ss erythroid progenitors/erythroblasts using viral vectors comprising a tumoricidal transgene operatively linked to the coding region of ss β-globin promoter/enhancer.

05/26/16
20160143977 

Stabilized omega-3 ophthalmic compositions


Stabilized ophthalmic compositions containing omega-3 oils are provided, which are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal.. .
Allergan, Inc.


05/26/16
20160143954 

Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues


The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature.
The Schepens Eye Research Institute, Inc.


05/26/16
20160143944 

Antimicrobial compositions comprising hypochlorous acid and silver


The present invention relates to methods and compositions for treating a surface characterized by microbial infection or colonization. Particularly, the methods of the present invention involve applying a hypohalous acid (e.g., hypochlorous acid) composition and a silver additive.
Puricoe, Inc.


05/26/16
20160143942 

Compositions and their use for removing cholesterol


The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide.
Cornell University


05/26/16
20160143885 

Treatment steroid responsive dermatoses


Invented is a method of treating steroid responsive dermatoses in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a compound selected from the group consisting of: n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof, and the compound n-{(1s)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof, to such mammal.. .
Novartis Ag


05/26/16
20160143844 

Drug delivery systems and use thereof


The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-vascular endothelial growth factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal.
Massachusetts Eye And Ear Infirmary


05/26/16
20160143738 

Biological constructs for treating damaged organs and tissue


Biological constructs that can be engineered into a variety of shapes and employed to treat, augment and/or support damaged or diseased mammalian organs and/or tissue related thereto. The shapes include jackets and bands that are configured to encase a preselected region of a mammalian organ..
Cormatrix Cardiovascular, Inc.


05/19/16
20160139153 

Biomarkers for seizures


The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject.
The Trustees Of The University Of Pennsylvania


05/19/16
20160138046 

Compositions and methods directed to crispr/cas genomic engineering systems


The invention relates to engineered crispr/cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the streptococcus pyogenes (s.
System Biosciences, Llc


05/19/16
20160138027 

Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)


Compositions and methods for treating diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) are disclosed. The invention is based in part on the discovery that protein mediator of amino acid signaling to mtor (mortor) is involved in amino acid-induced translocation of mtorc1 to lysosomes where mortor forms a signaling complex with mtorc1, ragulator, and rag gtpases, which controls protein synthesis.
The Board Of Trustees Of The Leland Stanford Junior University


05/19/16
20160137629 

Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi


The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (pet) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body.
Piramal Imaging Sa


05/19/16
20160136347 

Ambulatory lung assist device with implanted blood pump and oxygenator


The present disclosure provides a system for oxygenating blood. The system may include an implantable blood pump that may draw a supply of blood from the circulatory system of a mammalian subject, such as a human being.
Heartware, Inc.


05/19/16
20160136268 

Mammalian milk osteopontin for enhancing immune responsiveness


The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof..
Arla Foods Amba


05/19/16
20160136245 

Methods of treating pain using protein solutions


Methods and compositions for treating pain in mammalian subjects are provided. The methods include obtaining blood or a fraction of blood from the subject, measuring a therapeutic indicator in the blood or in the fraction blood, and administering an anti-inflammatory composition to the subject if the therapeutic indicator is equal to or above a threshold level.

05/19/16
20160136198 

Use of immobilization particles for removal of microorganisms and/or chemicals


Method for immobilizing a target microorganism or target chemical found in a mammal includes introducing into a gastrointestinal tract of the mammal immobilization particles including immobilization molecules capable of attaching to the target microorganism or the target chemical, which immobilization molecules are attached to one or more portions of a structure that is capable of inhibiting contact between tissues of the gastrointestinal tract and the target microorganisms or target chemicals attached to the immobilization molecules.. .
Nubiome, Inc.


05/19/16
20160136197 

Pharmaceutical compositions comprising a gpg oligodeoxynucleotide and cyclic di-gmp


The present invention relates to pharmaceutical compositions comprising an immunostimulatory amount of at least two immunopotentiators, wherein a first immunopotentiator is a non-methylated cytidyl guanosyl oligodeoxynucleotide (cpg odn) and a second immunopotentiator is 3′,5′-cyclic diguanylic acid (c-di-gmp), and a pharmaceutically acceptable carrier. The invention also relates to the use of such pharmaceutical compositions for the induction of an immune response against tumor-specific antigens.
Intervet Inc.


05/19/16
20160136149 

Heteroaryl linked quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/19/16
20160136126 

Pharmaceutical compositions of anisomelic acid and the use thereof


A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of anisomelic acid or salts thereof. The pharmaceutical composition may comprise anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof.

05/19/16
20160136119 

Dp2 antagonist and uses thereof


Described herein is the dp2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the dp2 antagonist, or a pharmaceutically acceptable salt thereof.
Brickell Biotech, Inc.


05/19/16
20160136115 

T type calcium channel inhibitors


The present invention provides novel t type calcium channel inhibitors of formula (i), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via t type calcium channels, wherein r1 is c1-c4 alkyl, hydroxy, or c1-c4 alkoxy; z is nh, nch3, o, s, or ch2; y is nh, o, or ch2 with the proviso that y and z are not the same; r2 is h, halo, nh2, c1-c4 alkyl, hydroxy, or c1-c4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and r3 is h, halo, nh2, c1-c4 alkyl, hydroxy, or c1-c4 alkoxy.. .
University Of Virginia Patent Foundation






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9306

4241

2 - 1 - 101